# DESCRIPTION

## BACKGROUND

- motivate atherosclerotic disease
- discuss HDL and cardiovascular risk
- limitations of HDL cholesterol levels
- motivate HDL function measurement
- discuss cell-based assays
- limitations of cell-based assays
- introduce alternative biochemical assays

## SUMMARY

- introduce new biochemical assay
- describe assay correlation with cell-based assays
- summarize assay utility

## Embodiment 1

- describe method of evaluating HDL function

## Embodiment 2

- define elevated HRA

## Embodiment 3

- specify AMPLEX RED reagent

## Embodiment 4

- specify AMPLEX ULTRARED reagent

## Embodiment 5

- exclude cholesterol oxidase

### Embodiment 6

- add cholesterol esterase

### Embodiment 7

- detect fluorescence over time

### Embodiment 8

- quantify fluorescence relative to maximum

### Embodiment 9

- quantify fluorescence relative to reference control

### Embodiment 10

- determine concentration from standard curve

### Embodiment 11

- use regression analysis for standard curve

### Embodiment 12

- normalize fluorescence by HDL concentration

### Embodiment 13

- use non-EDTA plasma sample

### Embodiment 14

- use serum sample

### Embodiment 15

- use apoB depleted serum sample

### Embodiment 16

- use fresh sample

### Embodiment 17

- use cryopreserved sample

### Embodiment 18

- use isolated HDL sample

### Embodiment 19

- isolate HDL by various methods

### Embodiment 20

- isolate HDL by PEG precipitation

### Embodiment 21

- isolate HDL by immunoaffinity capture

### Embodiment 22

- compare to control

### Embodiment 23

- use healthy subject sample as control

### Embodiment 24

- use positive control

### Embodiment 25

- use hydrogen peroxide as positive control

### Embodiment 26

- determine difference from negative control

### Embodiment 27

- use reaction mixture without cholesterol as negative control

### Embodiment 28

- subtract blank well value

### Embodiment 29

- perform in high throughput format

### Embodiment 30

- perform in multi-well plate

### Embodiment 31

- perform in microfluidic device

### Embodiment 32

- perform in droplet-based microfluidic system

### Embodiment 33

- define elevated HRA

### Embodiment 34

- define elevated HRA based on inflammatory index

### Embodiment 35

- determine presence or risk of atherosclerosis

### Embodiment 36

- record elevated HRA in patient medical record

### Embodiment 37

- maintain patient medical record

### Embodiment 38

- record diagnosis on medic alert article

### Embodiment 39

- record HRA levels on non-transient computer readable medium

### Embodiment 40

- determine HRA level as part of differential diagnosis

### Embodiment 41

- use non-human mammal subject

### Embodiment 42

- use human subject

### Embodiment 43

- treat or prophylaxis atherosclerosis

### Embodiment 44

- prescribe additional test

### Embodiment 45

- perform additional tests

### Embodiment 46

- perform blood test

### Embodiment 47

- perform stress test

### Embodiment 48

- prescribe treatment

### Embodiment 49

- administer pharmaceutical

### Embodiment 50

- administer specific pharmaceuticals

### Embodiment 51

- perform angioplasty or bypass surgery

### Embodiment 52

- provide kit for evaluating HDL function

### Embodiment 53

- include reagents for isolating HDL

### Embodiment 54

- include antibody for immunoaffinity capture

### Embodiment 55

- attach antibody to solid support

### Embodiment 56

- screen for agent that improves HDL function

### Embodiment 57

- contact HDL with test agent ex vivo

### Embodiment 58

- administer test agent to mammal

### DEFINITIONS

- define LDL
- define HDL and HDL component

### DETAILED DESCRIPTION

- introduce cardiovascular disease
- describe HDL and cardiovascular disease correlation
- motivate need for HDL function assessment
- describe limitations of previous HDL function assays
- introduce novel approach using AMPLEX RED
- describe advantages of new assay
- detail biochemical mechanism of AMPLEX RED
- describe use of immunoaffinity capture for HDL isolation
- highlight reproducibility of new assay
- describe applicability to large scale clinical studies
- correlate HRA with cardiovascular disease
- describe use of animal models to validate assay
- describe use of human studies to validate assay
- propose mechanism of HDL function
- describe detection of dysfunctional HDL
- describe applicability to biological samples
- describe effect of matrix effects on HRA
- describe effect of freeze-thaw on HRA
- describe effect of sample handling on HRA
- describe effect of long-term storage on HRA
- introduce HRA assays
- describe use of AMPLEX RED in HRA assays
- describe detection methods for HRA assays
- describe use of cholesterol esterase in HRA assays
- describe quantification of HRA
- describe normalization of HRA
- describe use of reference control samples
- describe use of standard curves for HRA quantification
- describe applicability to various biological samples
- describe isolation methods for HDL
- describe use of immunoaffinity capture for HDL isolation
- describe use of PEG precipitation for HDL isolation
- describe use of heparin MnCl2 precipitation for HDL isolation
- describe use of sodium phosphotungstate precipitation for HDL isolation
- describe use of dextran sulfate precipitation for HDL isolation
- describe use of microfluidic platforms for HRA assays
- describe use of droplet-based microfluidic systems
- introduce illustrative uses of HRA assays
- describe diagnostic/prognostic applications
- describe therapeutic applications
- describe screening applications for therapeutic agents

### EXAMPLES

- introduce example 1
- describe biochemical fluorometric method
- list materials and reagents
- describe preparation of dihydrorhodamine 123
- describe preparation of iron-free HEPES-buffered saline
- list reagents from AMPLEX RED Cholesterol Assay Kit
- describe HDL and LDL purification
- describe immunoaffinity capture of HDL
- describe measurement of HDL cholesterol
- describe measurement of total HDL protein
- describe detection of albumin
- describe HDL inflammatory index
- describe DHR-based cell-free assay of HDL function
- describe AMPLEX RED assay method A
- describe AMPLEX RED assay method B
- describe human subjects with coronary artery disease
- describe human immunodeficiency virus (HIV-1)-infected individuals
- describe healthy subjects
- describe exercise study participants
- describe mice
- describe apoE and LDLR null mice
- describe Western diet
- describe pravastatin treatment
- describe animal research committee approval
- describe HDL isolation using PEG precipitation
- describe HDL isolation using immunoaffinity capture
- describe HDL isolation using ultracentrifugation
- describe HDL isolation using FPLC
- describe HDL isolation using precipitation with polyethylene glycol
- define metabolic syndrome
- collect data on HIV cohort
- collect data on exercise study
- perform statistical analysis
- motivate AMPLEX RED
- describe AMPLEX RED reaction
- quantify cholesterol content of HDL
- measure lipid peroxidation of HDL
- determine rate of lipid peroxidation
- quantify endogenous lipid hydroperoxides
- study lipid probe interactions
- use HRP to overcome lipid probe interactions
- measure HRA of HDL
- detect dysfunctional HDL in vivo
- correlate AMPLEX RED with cell-based assay
- correlate AMPLEX RED with cell-free assay
- standardize AMPLEX RED assay
- use control sample to standardize assay
- adjust for HDL concentration
- study effect of freeze-thaw on HRA
- study effect of matrix on HRA
- study effect of sample handling on HRA
- use immunoaffinity capture of HDL
- isolate HDL using immunoaffinity capture
- measure HRA of isolated HDL
- compare different HDL kits
- normalize fluorescent readout by HDL protein
- assess reproducibility of AMPLEX RED assay
- use AMPLEX RED as marker of cardiovascular disease
- use AMPLEX RED as marker of biologic processes
- study association of HRA with exercise
- study association of HRA with metabolic disease
- study association of HRA with vascular disease
- study association of HRA with anthropometric parameters
- study association of HRA with inflammatory markers
- study association of HRA with lipids
- study association of HRA with glucose metabolism
- study association of HRA with insulin resistance
- study association of HRA with adipokines
- study association of HRA with cardiovascular risk factors
- perform multivariate analysis
- discuss results of AMPLEX RED assay
- discuss limitations of AMPLEX RED assay
- conclude utility of AMPLEX RED assay

### DISCUSSION

- discuss HDL phenotype and cardiovascular disease risk
- describe HDL heterogeneity
- discuss HDL functional properties
- motivate dysfunctional HDL
- describe limitations of cell-based assays
- introduce cell-free assay based on DCF
- discuss validation of DCF assay
- correlate DCF assay with other measures of HDL function
- discuss oxidation of HDL
- describe myeloperoxidase-mediated oxidation
- discuss ROS-mediated oxidation
- introduce DHR assay
- discuss validation of DHR assay
- correlate DHR assay with monocyte chemotaxis assay
- discuss limitations of DHR assay
- describe lipid-probe interactions
- discuss limitations of fluorescent probes
- introduce AMPLEX RED reagent
- describe properties of AMPLEX RED
- discuss use of AMPLEX RED in cell culture supernatants
- describe modification of AMPLEX RED assay
- discuss detection of lipid peroxidation
- describe use of cholesterol esterase
- discuss advantages of AMPLEX RED assay
- correlate AMPLEX RED assay with cell-based assays
- discuss use of immunoaffinity capture
- describe inter-assay variability
- discuss use of animal models
- correlate AMPLEX RED assay with biologic readout
- discuss effect of statins on HDL function
- discuss detection of dysfunctional HDL in HIV patients
- discuss correlation with surrogate measures of cardiovascular disease
- discuss oxidation in atherogenesis
- discuss matrix effects on HRA
- discuss freeze-thaw and sample handling effects
- discuss long-term storage effects
- conclude advantages of AMPLEX RED assay

### Acknowledgements

- acknowledge funding sources
- acknowledge partial funding for laboratory work

